CEL-SCI Corp
$ 5.01
-4.57%
10 Feb - close price
- Market Cap 42,127,800 USD
- Current Price $ 5.01
- High / Low $ 5.49 / 5.01
- Stock P/E N/A
- Book Value 1.99
- EPS -5.98
- Next Earning Report 2026-02-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.56 %
- ROE -1.76 %
- 52 Week High 20.40
- 52 Week Low 1.98
About
CEL-SCI Corporation (CVM), headquartered in Vienna, Virginia, is a pioneering biotechnology firm dedicated to advancing immunotherapy solutions for cancer and infectious diseases. Its lead candidate, Multikine, represents a novel approach by leveraging the body's immune response to target tumors, showcasing substantial potential in the oncology sector. With a strong and diverse pipeline addressing significant unmet medical needs, CEL-SCI is well-positioned to disrupt the biopharmaceutical landscape, appealing to institutional investors seeking to back innovative healthcare advancements.
Analyst Target Price
$42.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-23 | 2025-08-12 | 2025-05-13 | 2025-01-13 | 2024-12-31 | 2024-08-14 | 2024-05-15 | 2024-02-14 | 2023-12-21 | 2023-08-10 | 2023-05-12 | 2023-02-14 |
| Reported EPS | -0.86 | -1.36 | -2.3323 | -2.7 | -2.7003 | -0.14 | -0.14 | -0.14 | -0.16 | -0.19 | -0.19 | -0.18 |
| Estimated EPS | None | None | None | -3.3 | -0.1 | -0.13 | -0.14 | -0.14 | -0.16 | -0.16 | -0.17 | -0.21 |
| Surprise | 0 | 0 | 0 | 0.6 | -2.6003 | -0.01 | 0 | 0 | 0 | -0.03 | -0.02 | 0.03 |
| Surprise Percentage | None% | None% | None% | 18.1818% | -2600.3% | -7.6923% | 0% | 0% | 0% | -18.75% | -11.7647% | 14.2857% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-13 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVM
2026-01-27 00:29:03
Cel-Sci Corp's CEO, Kersten Geert R., recently purchased 38,023 shares of common stock for $200,000, increasing his direct ownership to 120,815 shares. The company also announced revisions to its Shareholder Rights Agreement, the details of which were not publicly disclosed. These moves reflect ongoing corporate governance efforts by Cel-Sci.
2026-01-26 20:27:53
Shares of CEL-SCI Corp. (CVM) rallied over 7% after its CEO, Kersten Geert R., purchased 38,023 shares of the company stock for approximately $200,000. This insider buying signals confidence in the company, which is known for its experimental cancer treatment, Multikine. Cel-Sci plans to begin a confirmatory registration study for Multikine in spring 2026, with an aim to seek approval by 2028.
2026-01-26 14:52:25
Cel-Sci Corporation CEO Kersten Geert R. recently purchased 38,023 shares of the company's common stock for approximately $200,000, increasing his direct ownership to 120,815 shares. Additionally, Cel-Sci's Board of Directors approved revisions to its Shareholder Rights Agreement, a development disclosed in a recent SEC filing without specific details. These corporate governance efforts reflect the company's strategic management initiatives.
2026-01-26 14:27:53
Cel Sci Corp CEO Kersten Geert R. recently purchased 38,023 shares of common stock for $200,000, increasing his direct ownership to 120,815 shares. Additionally, Cel-Sci Corporation announced revisions to its Shareholder Rights Agreement, a move reflecting ongoing corporate governance efforts. These developments were disclosed in recent SEC filings.
2026-01-26 10:00:00
Geert Kersten, CEO of CEL-SCI Corp (CVM), recently purchased 38,023 shares, increasing his total holdings to 120,815 shares. This transaction is part of a trend of insider buying at the company over the past year, with four insider purchases and no sales. Investors often interpret insider buying as a positive sign of confidence in the company's future, especially at its current trading price of $5.26 per share.
2025-12-29 14:09:58
CEL-SCI Corporation (CVM) reported its fiscal year 2025 financial results, emphasizing significant progress with its cancer drug Multikine. The company is preparing for a 212-patient Confirmatory Registration Study in the U.S. for head and neck cancer, with enrollment expected in Spring 2026, and also secured Breakthrough Medicine Designation for Multikine in Saudi Arabia. This dual focus on U.S. regulatory advancements and international market expansion, alongside positive financial results including a decreased net loss and successful capital raises, underscores a promising outlook for Multikine's development and market entry.
